DK2462165T3 - Fremgangsmåde til in-vivo proliferation af regulatoriske T-celler - Google Patents

Fremgangsmåde til in-vivo proliferation af regulatoriske T-celler Download PDF

Info

Publication number
DK2462165T3
DK2462165T3 DK10807012.9T DK10807012T DK2462165T3 DK 2462165 T3 DK2462165 T3 DK 2462165T3 DK 10807012 T DK10807012 T DK 10807012T DK 2462165 T3 DK2462165 T3 DK 2462165T3
Authority
DK
Denmark
Prior art keywords
cells
treg
tnfr25
mice
foxp3
Prior art date
Application number
DK10807012.9T
Other languages
English (en)
Inventor
Eckhard R Podack
Taylor Schreiber
Dietlinde-Maria Wolf
Original Assignee
Univ Miami
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami filed Critical Univ Miami
Application granted granted Critical
Publication of DK2462165T3 publication Critical patent/DK2462165T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Claims (6)

1. En TNFR-agonist til anvendelse ved en fremgangsmåde til forsinkelse af akut afstødning af e transplanteret organ eller væv i et individ, hvorved TNFR-agonisten er et monoklonalt antilegeme, som specifikt binder TNFR25, eller hvorved TNFR-agonisten er en tumor-nekrosefaktor-lignende ligand-1A-fusion (TFlA-lg-fusion).
2. TNFR-agonist til anvendelse ifølge krav 1, hvorved det monoklonale antilegeme er af lgG-isotypen.
3. TNFR-agonist til anvendelse ifølge krav 1, hvorved TNFR-agonisten inducerer formeringen af CD4+FoxP3+ - celler i individet.
4. Anvendelse af en TNFR-agonist ved fremstillingen af et medikament til forsinkelse af akut afstødning af et transplanteret organ eller væv i et individ, hvorved TNFR-agonisten er et monoklonalt antilegeme, som specifikt binder TNFR25, eller hvorved TNFR-agonisten er en TFlA-lg-fusion.
5. Anvendelse ifølge krav 4, hvorved det monoklonale antilegeme er af lgG-isotypen.
6. Anvendelse ifølge krav 4, hvorved TNFR-agonisten inducerer formering af CD4+FoxP3+ - celler i individet.
DK10807012.9T 2009-08-03 2010-08-03 Fremgangsmåde til in-vivo proliferation af regulatoriske T-celler DK2462165T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27329909P 2009-08-03 2009-08-03
PCT/US2010/044218 WO2011017303A1 (en) 2009-08-03 2010-08-03 Method for in vivo expansion of t regulatory cells

Publications (1)

Publication Number Publication Date
DK2462165T3 true DK2462165T3 (da) 2016-08-29

Family

ID=43544621

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10807012.9T DK2462165T3 (da) 2009-08-03 2010-08-03 Fremgangsmåde til in-vivo proliferation af regulatoriske T-celler

Country Status (12)

Country Link
US (3) US9499627B2 (da)
EP (1) EP2462165B1 (da)
JP (1) JP2013501057A (da)
KR (2) KR102033276B1 (da)
CN (1) CN102770455B (da)
AU (1) AU2010279637B2 (da)
CA (1) CA2806840C (da)
DK (1) DK2462165T3 (da)
ES (1) ES2586837T3 (da)
IL (1) IL217871A (da)
SG (2) SG178125A1 (da)
WO (1) WO2011017303A1 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100702699B1 (ko) * 2000-06-13 2007-04-02 삼성전자주식회사 수직 블랭킹 및 스포트 제거 결합 회로
JP4797290B2 (ja) * 2001-07-12 2011-10-19 株式会社サタケ 粉砕ロール装置
KR100705066B1 (ko) * 2004-08-09 2007-04-06 엘지전자 주식회사 전기 오븐 레인지의 이중 바닥 고정 구조
KR100740140B1 (ko) * 2004-08-12 2007-07-16 이기수 스팽글 제조용 컷팅장치
KR100766017B1 (ko) * 2004-09-23 2007-10-10 유계춘 스티로폴 관
DE102004047293A1 (de) * 2004-09-29 2006-04-13 Trw Automotive Electronics & Components Gmbh & Co. Kg Druckschalter mit Schutz der Membran gegen Überdehnung
TWI275484B (en) * 2004-10-15 2007-03-11 Bobst Sa Method and station for unblanked sheet delivery in a machine processing plate elements
KR100704734B1 (ko) * 2004-11-02 2007-04-06 주식회사 제철세라믹 엘리베이터용 균형추
KR100722052B1 (ko) * 2004-11-05 2007-05-25 엘지전자 주식회사 얼음저장용기 결합구조
KR100729382B1 (ko) * 2004-12-30 2007-06-15 김진만 발받침대를 구비한 자동차용 매트
KR100727557B1 (ko) * 2005-03-14 2007-06-14 현대자동차주식회사 칩 브레이커가 구비된 실린더 헤드
KR100748521B1 (ko) * 2005-03-17 2007-08-13 엘지전자 주식회사 정수필터를 구비한 냉장고
KR100749763B1 (ko) * 2005-03-17 2007-08-17 삼성전자주식회사 급수호스 연결장치
KR100742346B1 (ko) * 2005-05-03 2007-07-25 삼성전자주식회사 직류 전원 전환 장치
KR100703181B1 (ko) * 2005-08-17 2007-04-06 엘지이노텍 주식회사 멀티 출력전압 전원장치
CN101253199B (zh) 2005-08-30 2019-06-14 迈阿密大学 免疫调节肿瘤坏死因子受体25(tnfr25)的激动剂、拮抗剂和免疫毒素
KR100703667B1 (ko) * 2005-09-06 2007-04-06 엘지전자 주식회사 밀폐형 압축기의 작동유체 과열방지장치
KR100772727B1 (ko) * 2005-09-23 2007-11-02 차용훈 용접 대상물 지지장치
KR100702333B1 (ko) * 2005-11-03 2007-04-06 박지영 고추 꼭지 제거장치
KR100777164B1 (ko) * 2005-12-27 2007-11-29 한국건설기술연구원 하천정화시설의 유입구 개폐장치
KR100759202B1 (ko) * 2005-12-30 2007-09-14 유영옥 보조위생깔개
KR100756277B1 (ko) * 2006-01-18 2007-09-07 백남일 버클
KR100750577B1 (ko) * 2006-01-24 2007-08-21 강성일 다층 구조의 고효율 멤브레인 산기관
KR100779035B1 (ko) * 2006-02-15 2007-11-23 주식회사 제이리빙 욕조용 에이프런
KR100748612B1 (ko) * 2006-03-08 2007-08-10 강윤범 다기능 휴대용 소화기
KR100719748B1 (ko) * 2006-03-10 2007-05-17 지멘스 오토모티브 주식회사 자동차 시동 장치
KR100712947B1 (ko) * 2006-03-15 2007-05-04 이원모 설치 교체가 용이한 담배꽁초 자동소화파이프
KR100787617B1 (ko) * 2006-03-16 2007-12-21 김성규 수동 분무기
KR100711906B1 (ko) * 2006-04-03 2007-04-27 신중 팬티
KR100702590B1 (ko) * 2006-04-12 2007-04-02 김호남 사무기기용 다용도 테이블
KR100760369B1 (ko) * 2006-05-10 2007-09-20 권오식 편심조정이 필요없는 2줄 이상의 선재 피복장치
KR100708477B1 (ko) * 2006-05-15 2007-04-18 삼성전자주식회사 주파수 보상장치
KR100772603B1 (ko) * 2006-05-16 2007-11-07 주식회사 유성반도체 화재 감지기
KR100768704B1 (ko) * 2006-05-24 2007-10-23 박용자 고주파유도가열을 이용한 온풍장치
KR100723452B1 (ko) * 2006-06-13 2007-05-31 김태수 수영용 보조기구
KR100721327B1 (ko) * 2006-06-23 2007-05-25 주식회사 마이크로필터 정수기 필터 어셈블리
KR100774985B1 (ko) * 2006-06-29 2007-11-09 박길자 차량의 흘러내림 방지용 제어밸브
KR100748427B1 (ko) * 2006-07-05 2007-08-13 김세영 발의 구조 및 보행에 적합한 인체공학적인 신발 밑창
KR100745973B1 (ko) * 2006-07-08 2007-08-08 한원흠 물비누(왁스)가 나오는 다용도 전동솔과 구현 방법
KR100776578B1 (ko) * 2006-07-20 2007-11-15 라병렬 비닐하우스 내의 복수의 터널용 덮개 안내장치
KR100761506B1 (ko) * 2006-07-26 2007-09-27 린나이코리아 주식회사 가스밸브용 베이스플레이트
KR100742390B1 (ko) * 2006-07-28 2007-07-24 이상도 터널형 신발 밑창과 그 제조 방법
KR100760192B1 (ko) * 2006-08-04 2007-09-20 세종산업 주식회사 캐스터 브레이크 장치
KR100730308B1 (ko) * 2006-08-11 2007-06-19 주식회사 빅솔론 출력방향 조절을 위한 네크를 구비하는 디스플레이 장치
KR100757965B1 (ko) * 2006-08-21 2007-09-12 한국오므론전장주식회사 버저 내장형 경보장치
KR100751507B1 (ko) * 2006-08-25 2007-08-23 이창석 회전 가능한 칫솔
KR100749059B1 (ko) * 2006-08-25 2007-08-13 삼성전자주식회사 식기세척기 및 그 제어방법
KR100768169B1 (ko) * 2006-08-30 2007-10-17 위니아만도 주식회사 김치저장고의 응축기 방진구조
KR100737120B1 (ko) * 2006-08-31 2007-07-06 박병인 재료의 혼합 및 균질화장치
KR100762278B1 (ko) * 2006-09-05 2007-10-01 한국단자공업 주식회사 백라이트 램프 고정 소켓
KR100766818B1 (ko) * 2006-09-05 2007-10-17 창인건설(주) 분수 구동장치
KR100754248B1 (ko) * 2006-09-18 2007-09-03 김동현 스팀진공청소기
KR100735844B1 (ko) * 2006-10-16 2007-07-06 김형택 세척 및 청소용구
KR100757038B1 (ko) * 2006-10-23 2007-09-07 김현중 염색약 도포장치
KR100788738B1 (ko) * 2006-11-09 2007-12-26 동서코퍼레이션(주) 조합 분수노즐
KR100759361B1 (ko) * 2006-11-13 2007-09-19 김경완 면취기의 에어 공급 밸브 결합구조
KR100771344B1 (ko) * 2006-11-17 2007-10-29 삼성전기주식회사 초슬림 스핀들모터 조립용 지그조립체
KR100751421B1 (ko) * 2006-12-13 2007-08-23 (주) 그룹원이앤지 형광등 소켓
KR100768529B1 (ko) * 2006-12-27 2007-10-18 주식회사 한국 종합엔지니어링 상수도용 고무 디스크의 변형 방지 기능을 갖는 역지밸브
KR100752766B1 (ko) * 2006-12-29 2007-08-29 송재창 급속 구이부를 갖는 다단 회전식 바베큐 장치
KR100777590B1 (ko) * 2007-01-19 2007-11-28 이준항 떡 제조장치
KR100729443B1 (ko) * 2007-03-02 2007-06-15 정재억 다단 습식집진기
KR100776048B1 (ko) * 2007-05-25 2007-11-16 가아전기(주) 옥외용 배전반의 감전사고 방지장치
KR100781968B1 (ko) * 2007-08-14 2007-12-06 코리아디지탈 주식회사 광경로 길이를 변경할 수 있는 비분산 적외선 가스 농도측정장치
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US11090363B2 (en) 2009-07-10 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Vasoactive intestinal peptide release from microparticles
US8846098B2 (en) 2009-07-10 2014-09-30 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Artificial cell constructs for cellular manipulation
JP2013501057A (ja) 2009-08-03 2013-01-10 ユニバーシティー・オブ・マイアミ 制御性ｔ細胞のｉｎｖｉｖｏにおける増殖
KR20210041631A (ko) * 2013-01-09 2021-04-15 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법
EP2978440B1 (en) 2013-03-27 2019-10-02 Cedars-Sinai Medical Center Treating fibrosis by inhibiting tl1a and diagnosing fibrosis by detecting il31ra
US10316083B2 (en) 2013-07-19 2019-06-11 Cedars-Sinai Medical Center Signature of TL1A (TNFSF15) signaling pathway
CN103592439B (zh) * 2013-09-03 2015-10-21 天津亿美诺生物科技有限公司 人尿路上皮癌特异性抗体及其应用
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
KR101705446B1 (ko) * 2014-04-29 2017-02-09 가톨릭대학교 산학협력단 면역질환 치료효과를 갖는 신규한 화합물 및 이의 용도
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en) 2014-05-05 2015-11-12 Lycera Corporation BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
CN107075545A (zh) 2014-07-30 2017-08-18 哈佛学院院长及董事 探针文库构建
US9982057B2 (en) 2014-11-17 2018-05-29 Pelican Therapeutics, Inc. Human TNFRSF25 antibody
EP3292119A4 (en) 2015-05-05 2018-10-03 Lycera Corporation DIHYDRO-2H-BENZO[b][1,4]OXAZINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE
EP3294336A1 (en) * 2015-05-15 2018-03-21 Cedars-Sinai Medical Center Models, methods and compositions for treating inflammatory bowel disease
US10611740B2 (en) 2015-06-11 2020-04-07 Lycera Corporation Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
WO2017077715A1 (en) * 2015-11-02 2017-05-11 La Jolla Institute For Allergy & Immunology Method and medicament for treating airway and/or lung diseases
CN118773299A (zh) 2016-03-17 2024-10-15 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
JP6961625B2 (ja) * 2016-06-09 2021-11-10 ペリカン セラピューティクス，インコーポレイテッド 抗ｔｎｆｒｓｆ２５抗体
KR20190082815A (ko) 2016-10-26 2019-07-10 세다르스-신나이 메디칼 센터 중화 항-tl1a 단일 클론 항체
WO2018218150A1 (en) 2017-05-26 2018-11-29 President And Fellows Of Harvard College Systems and methods for high-throughput image-based screening
EP3450981A1 (en) * 2017-08-28 2019-03-06 Trizell GmbH Btnl8 as a marker for tregs
WO2019166658A1 (en) * 2018-03-01 2019-09-06 Fundación Para La Investigación Biomédica Del Hospital Gregorio Marañón Method for obtaining regulatory t cells derived from thymic tissue and use of said cells as cell immunotherapy in immune system disorders
JP7332627B2 (ja) 2018-04-25 2023-08-23 プロメテウス バイオサイエンシーズ，インク． 最適化された抗ｔｌ１ａ抗体
EP3842522A4 (en) * 2018-08-22 2021-09-22 Osaka University PROCESS FOR THE PRODUCTION OF T-REGULATORY LYMPHOCYTES
US20220298252A1 (en) * 2019-08-30 2022-09-22 Pelican Therapeutics, Inc. Methods of treating cancer using tnfrsf25 antibodies
US20220340672A1 (en) * 2019-09-26 2022-10-27 Pelican Therapeutics, Inc. Tnfrsf25-mediated treatments of immune diseases and disorders
JP7504992B2 (ja) 2019-10-24 2024-06-24 プロメテウス バイオサイエンシーズ，インク． Ｔｎｆ様リガンド１ａ（ｔｌ１ａ）に対するヒト化抗体およびその使用
CN110938632A (zh) * 2020-01-02 2020-03-31 郑州大学 一种特异结合tnf-r1的适配体及其筛选方法和应用
WO2024071039A1 (ja) * 2022-09-26 2024-04-04 レグセル株式会社 キメラ抗原受容体（ｃａｒ）を含む誘導性制御性ｔ細胞

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190495A (en) 1976-09-27 1980-02-26 Research Corporation Modified microorganisms and method of preparing and using same
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
NZ201418A (en) 1982-07-28 1986-08-08 Barmac Ass Ltd Mineral breaker with centrifugal breaking action
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4870009A (en) 1982-11-22 1989-09-26 The Salk Institute For Biological Studies Method of obtaining gene product through the generation of transgenic animals
US4654307A (en) 1983-02-17 1987-03-31 The Research Foundation Of State University Of New York Novel bacteria containing a plasmid having a tRNA code
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5175269A (en) 1984-01-30 1992-12-29 Enzo Diagnostics, Inc. Compound and detectable molecules having an oligo- or polynucleotide with modifiable reactive group
US5118627A (en) 1984-02-27 1992-06-02 Amgen Papova virus construction
US4952496A (en) 1984-03-30 1990-08-28 Associated Universities, Inc. Cloning and expression of the gene for bacteriophage T7 RNA polymerase
US5212286A (en) 1984-04-19 1993-05-18 Scios Nova Inc. Atrial natriuretic/vasodilator peptide compounds
US4761367A (en) 1984-11-07 1988-08-02 The University Of North Carolina At Chapel Hill Vectors suitable for detection of eukaryotic DNA regulatory sequences
US4719179A (en) 1984-11-30 1988-01-12 Pharmacia P-L Biochemicals, Inc. Six base oligonucleotide linkers and methods for their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5859208A (en) 1988-07-06 1999-01-12 Fiddes; John C. Human basic fibroblast growth factor analog
US5198343A (en) 1986-08-05 1993-03-30 Transgene, S.A. Method for expressing a heterologous protein in a dapD- mutant of E. coli and the strain obtained
US5187153A (en) 1986-11-17 1993-02-16 Scios Nova Inc. Methods of treatment using Alzheimer's amyloid polypeptide derivatives
US5220013A (en) 1986-11-17 1993-06-15 Scios Nova Inc. DNA sequence useful for the detection of Alzheimer's disease
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5510099A (en) 1987-05-01 1996-04-23 Stratagene Mutagenesis testing using transgenic non-human animals carrying test DNA sequences
US5229279A (en) 1987-06-29 1993-07-20 Massachusetts Institute Of Technology Method for producing novel polyester biopolymers
US5223483A (en) 1987-10-22 1993-06-29 Merck & Co., Inc. Cysteine-modified acidic fibroblast growth factor
JP3095168B2 (ja) 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5215907A (en) 1989-02-24 1993-06-01 Oklahoma Medical Research Foundation Thermostable acid protease from sulfolobus acidocaldarius
US5173403A (en) 1989-02-24 1992-12-22 Oklahoma Medical Research Foundation Thermostable acid protease from sulfolobus acidocaldarius and gene
US5242687A (en) 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
JP2833773B2 (ja) 1989-03-31 1998-12-09 三信工業株式会社 船外機
US5244805A (en) 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5218088A (en) 1989-11-02 1993-06-08 Purdue Research Foundation Process for preparing dithiophosphate oligonucleotide analogs via nucleoside thiophosphoramidite intermediates
CA2076975A1 (en) 1990-02-28 1991-08-29 Kevin W. Moore Mammalian expression vectors
US5212058A (en) 1990-05-09 1993-05-18 Massachusetts Institute Of Technology Nucleic acid encoding ubiquitin-specific proteases
US5122463A (en) 1990-05-17 1992-06-16 Massachusetts Institute Of Technology Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor
DE4017595A1 (de) 1990-05-31 1991-12-05 Consortium Elektrochem Ind Maltopentaose produzierende amylasen
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
US5266317A (en) 1990-10-04 1993-11-30 University Of Georgia Research Foundation, Inc. Insect-specific paralytic neurotoxin genes for use in biological insect control: methods and compositions
US5462990A (en) 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
WO1993001286A2 (en) 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
US5243041A (en) 1991-08-22 1993-09-07 Fernandez Pol Jose A DNA vector with isolated CDNA gene encoding metallopanstimulin
US5714323A (en) 1991-08-30 1998-02-03 The University Of Medecine And Dentistry Of New Jersey Over expression of single-stranded molecules
DE4140512C1 (da) 1991-12-09 1993-04-08 A. Raymond & Cie, Grenoble, Fr
US5444149A (en) 1992-05-11 1995-08-22 Duke University Methods and compositions useful in the recognition, binding and expression of ribonucleic acids involved in cell growth, neoplasia and immunoregulation
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5434065A (en) 1993-05-06 1995-07-18 President And Fellows Of Harvard College In vivo selection of microbial virulence genes
AU7568094A (en) 1993-08-12 1995-03-14 Cytotherapeutics, Inc. Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US5700657A (en) 1993-12-13 1997-12-23 Genzyme Corporation Vectors and vector systems including genes encoding tumor suppressor proteins and producer cells transformed thereby
ES2146741T3 (es) 1993-12-17 2000-08-16 Novartis Ag Derivados de rapamicina utiles como inmunosupresores.
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
IL109558A (en) 1994-05-04 2004-08-31 Yissum Res Dev Co DNA structures Derived from the SV40 virus that include DNA sequences External
CA2194361A1 (en) 1994-07-08 1996-01-25 Stanley L. Lin Method for identifying nucleic acids encoding c-fos promoter activating proteins
US20030129189A1 (en) 1994-11-07 2003-07-10 Guo-Liang Yu Tumor necrosis factor-gamma
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US5792647A (en) 1995-02-13 1998-08-11 The Johns Hopkins University Bacterial catabolism of chitin
US6254874B1 (en) 1995-04-13 2001-07-03 President And Fellows Of Harvard College Attenuated auxotrophic microorganisms having a combination of non-attenuating mutations and method for making same
CA2223103A1 (en) 1995-06-06 1996-12-12 Isis Pharmaceuticals Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
PT833828E (pt) 1995-06-09 2003-02-28 Novartis Ag Derivados de rapamicina
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
TW557297B (en) 1997-09-26 2003-10-11 Abbott Lab Rapamycin analogs having immunomodulatory activity, and pharmaceutical compositions containing same
US20020111325A1 (en) 1997-11-03 2002-08-15 Human Genome Sciences, Inc. VEGI, an inhibitor of angiogenesis and tumor growth
JP4441112B2 (ja) 1997-11-03 2010-03-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 新脈管形成および腫瘍増殖のインヒビターであるｖｅｇｉ
KR100743894B1 (ko) 1998-02-27 2007-07-30 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 백신, 면역치료제 및 그의 이용 방법
US7300774B1 (en) 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands
EP1141027A1 (en) 1999-01-15 2001-10-10 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
ES2421720T3 (es) 1999-04-12 2013-09-05 Genentech Inc Homólogos del factor de necrosis tumoral y ácidos nucleicos que los codifican
CA2371114A1 (en) 1999-04-22 2000-11-02 Human Genome Sciences, Inc. Death domain containing receptors
US6872718B1 (en) 1999-08-20 2005-03-29 Takeda Chemical Industries, Ltd. Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof and agents
EP1212331B1 (en) 1999-08-24 2004-04-21 Ariad Gene Therapeutics, Inc. 28-epirapalogs
MXPA02005069A (es) 1999-11-19 2003-09-25 Wegmann Keith W Agentes de enlace especificos para t3 y metodos para su uso.
DE19963859A1 (de) 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
US6652854B2 (en) 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L
CA2426765C (en) 2000-10-24 2012-06-05 Shunichi Shiozawa Genomes participating in rheumatoid arthritis, method of the diagnosis thereof, method of evaluating the onset possibility thereof, diagnostic kit for detecting them and therapeutic method and remedies for rheumatoid arthritis
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2002094192A2 (en) 2001-05-24 2002-11-28 Human Genome Sciences, Inc. Antibodies against tumor necrosis factor delta (april)
WO2002100345A2 (en) 2001-06-11 2002-12-19 The Trustees Of The University Of Pennsylvania Vaccines, immunotherapeutics and methods of using the same
IL159478A0 (en) 2001-06-22 2004-06-01 Daiichi Suntory Pharma Co Ltd Remedies for eosinophilic diseases
ES2345329T3 (es) 2001-11-09 2010-09-21 Georgetown University Nueva isoforma del inhibidor del crecimiento celular endotelial vascular (vegi).
US20050123536A1 (en) * 2001-11-20 2005-06-09 Che-Leung Law Treatment of immunological disorders using anti-dc30 antibodies
AU2002333502A1 (en) 2002-02-10 2003-09-04 Apoxis Sa Fusion constructs containing active sections of tnf ligands
CN1446833A (zh) 2003-02-08 2003-10-08 复旦大学 一种温敏性可降解微凝胶及其制备方法
ES2428321T3 (es) * 2003-08-20 2013-11-07 University Of Miami Composiciones y métodos para tratar la enfermedad del pulmón inflamado
AU2005206746B2 (en) * 2004-01-08 2008-08-28 Regents Of The University Of California Regulatory t cells suppress autoimmunity
US7723454B2 (en) 2004-02-03 2010-05-25 The United States Of America As Represented By The Secretary Of The Navy Coating of organic fibers with siloxane-carborane polymers
US20090317388A1 (en) 2005-05-25 2009-12-24 Linda Burkly Tl1a in treatment of disease
CN101253199B (zh) * 2005-08-30 2019-06-14 迈阿密大学 免疫调节肿瘤坏死因子受体25(tnfr25)的激动剂、拮抗剂和免疫毒素
WO2007041317A2 (en) 2005-09-29 2007-04-12 Viral Logic Systems Technology Corp. Immunomodulatory compositions and uses therefor
WO2010042697A1 (en) * 2008-10-08 2010-04-15 University Of Miami Regulation of lymphocytes and uses therefor
US20120029472A1 (en) 2008-12-19 2012-02-02 University Of Miami Tnfr25 agonists to enhance immune responses to vaccines
JP2013501057A (ja) 2009-08-03 2013-01-10 ユニバーシティー・オブ・マイアミ 制御性ｔ細胞のｉｎｖｉｖｏにおける増殖
WO2011106707A2 (en) * 2010-02-26 2011-09-01 Human Genome Sciences, Inc. Antibodies that specifically bind to dr3
CN102453097A (zh) 2010-10-27 2012-05-16 上海科新生物技术股份有限公司 抑制血管新生的融合蛋白vf及药物组合物和应用
JP2014518883A (ja) 2011-05-20 2014-08-07 ガバメント・オブ・ザ・ユナイテッド・ステイツ，アズ・リプリゼンテッド・バイ・ザ・セクレタリー，デパートメント・オブ・ヘルス・アンド・ヒューマン・サーヴィシズ Ｔ細胞媒介疾病の病態を改善させるためのｔｌ１ａ−ｄｒ３相互作用の遮断及びその抗体
WO2012170072A1 (en) 2011-06-06 2012-12-13 Immungene, Inc. Engineered antibody-tnfsf member ligand fusion molecules
KR20210041631A (ko) 2013-01-09 2021-04-15 유니버시티 오브 마이애미 TL1A-Ig 융합 단백질을 사용한 T 조절 세포의 조절을 위한 조성물 및 방법

Also Published As

Publication number Publication date
ES2586837T3 (es) 2016-10-19
IL217871A0 (en) 2012-03-29
EP2462165B1 (en) 2016-05-11
EP2462165A4 (en) 2013-04-03
SG10201502330TA (en) 2015-05-28
WO2011017303A1 (en) 2011-02-10
US9499627B2 (en) 2016-11-22
AU2010279637A1 (en) 2012-03-15
KR20190000910A (ko) 2019-01-03
AU2010279637B2 (en) 2012-08-23
CA2806840C (en) 2019-08-27
EP2462165A1 (en) 2012-06-13
US10934364B2 (en) 2021-03-02
CN102770455B (zh) 2017-02-08
CA2806840A1 (en) 2011-02-10
CN102770455A (zh) 2012-11-07
IL217871A (en) 2016-05-31
KR20120089259A (ko) 2012-08-09
SG178125A1 (en) 2012-03-29
US20170226218A1 (en) 2017-08-10
KR102033276B1 (ko) 2019-10-16
US20180230226A1 (en) 2018-08-16
US20120135011A1 (en) 2012-05-31
JP2013501057A (ja) 2013-01-10

Similar Documents

Publication Publication Date Title
US10934364B2 (en) Method for in vivo expansion of T regulatory cells
Fu et al. Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
Elgueta et al. Molecular mechanism and function of CD40/CD40L engagement in the immune system
JP5164167B2 (ja) 免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
AU2020200315A1 (en) Use of cart19 to deplete normal b cells to induce tolerance
JP4741074B2 (ja) Ｏｘ−４０レセプター結合因子又はそれをコードする核酸を含む組成物並びに抗原特異的免疫応答を増強するための方法
Zhang et al. Activation of OX40 augments Th17 cytokine expression and antigen-specific uveitis
EP2787005A1 (en) Targeted cancer immune therapy
KR102423631B1 (ko) 케모카인 억제제, 콜로니 자극 인자 억제제 및 면역항암제를 포함하는 암의 예방 또는 치료용 조성물 및 병용 요법
KR20240024047A (ko) Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법
US20240226168A1 (en) Engineered nk cells and uses thereof
JP4780540B2 (ja) サバイビン由来癌抗原ペプチド
Fukushima et al. Roles of OX40 in the development of murine experimental allergic conjunctivitis: exacerbation and attenuation by stimulation and blocking of OX40
US20110195048A1 (en) Regulation of lymphocytes and uses therefor
Reil VAX014 Efficacy in the B16F10 Mouse Melanoma Model: A Novel Oncolytic Immunotherapy for Melanoma
Rajangam et al. Adoptive T-Cell Therapy for the Treatment of Lung Cancer
Pilgrim Characterisation of the immunomodulatory action of a unique anti-cxcr3 monoclonal antibody exploiting a conserved human and murine epitope for transplantation